This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Celldex Therapeutics Inc. (CLDX): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Celldex Therapeutics (CLDX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.5%. By the end of trading, Celldex Therapeutics rose $1.41 (7.4%) to $20.36 on average volume. Throughout the day, 2,699,027 shares of Celldex Therapeutics exchanged hands as compared to its average daily volume of 1,871,100 shares. The stock ranged in a price between $19.28-$20.50 after having opened the day at $19.54 as compared to the previous trading day's close of $18.95. Other companies within the Health Care sector that increased today were: Galectin Therapeutics (GALT), up 21.7%, Savient Pharmaceuticals (SVNT), up 18.6%, GW Pharmaceuticals PLC ADR (GWPH), up 14.8% and Response Genetics (RGDX), up 14.5%.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Celldex Therapeutics has a market cap of $1.5 billion and is part of the drugs industry. Shares are up 182.4% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow.

On the negative front, Biota Pharmaceuticals (BOTA), down 62.7%, Vical Incorporated (VICL), down 57.3%, Mast Therapeutics (MSTX), down 41.4% and Inovio Pharmaceuticals (INO), down 21.4% , were all laggards within the health care sector with Regeneron Pharmaceuticals (REGN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR (XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care (RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Submit an article to us!
DOW 17,011.13 +32.00 0.19%
S&P 500 1,990.89 +4.38 0.22%
NASDAQ 4,529.29 +2.8080 0.06%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs